✦ LIBER ✦

The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma

✍ Scribed by James C. Yang; Suzanne L. Topalian; Douglas J. Schwartzentruber; David R. Parkinson; Francesco M. Marincola; Jeffrey. S. Weber; Claudia A. Seipp; Donald E. White; Steven A. Rosenberg

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 707 KB
Volume: 76
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19950815)76:4<687::aid-cncr2820760424>3.0.co;2-m

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The hematologic toxicity of interleukin-

The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma

✍ Mark P. Macfarlane; James C. Yang; Anshu S. Guleria; Richard L White Jr.; Claudi 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 744 KB

Phase I/II study of thalidomide in combi

Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma

✍ Robert J. Amato; Margaret Morgan; Anish Rawat 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Long-term immunotherapy with low-dose in

Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma

✍ Carlo Buzio; Simeone Andrulli; Rosaria Santi; Laura Pavone; Rodolfo Passalacqua; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Phase iii randomized trial of interleuki

Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

✍ Teresa Murray Law; Robert J. Motzer; Madhu Mazumdar; Kenneth W. Sell; Philip Wal 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 723 KB

Background. Treatment with interleukin-2 (IL-2) and lymphokine-activated killer cells (LAK) resulted in responses in some patients with advanced renal cell carcinoma (RCC). However, the relative therapeutic benefit of the addition of LAK to IL-2 was unknown. Methods. A randomized Phase I11 trial wa

Phase II trial of recombinant human inte

Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: Implications for the treatment of patients with metastatic melanoma

✍ Omar Eton; Moshe Talpaz; Kyoo H. Lee; Jeanne M. Rothberg; Joanna M. Brell; Rober 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 664 KB

Cytotoxic In vitro function in patients

Cytotoxic In vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy effects of activation with recombinant interleukin-2

✍ Cristina Feruglio; Renato Zambello; Livio Trentin; Pietro Bulian; Tiziano France 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 658 KB